Xilio Therapeutics is a biotechnology company advancing next-generation cancer immunotherapies designed to improve patient outcomes by unleashing the power of the immune system selectively at the site of the tumor. The company’s tumor-selective immunotherapies are based on its proprietary technology, which maximizes the potency of proven immuno-oncology therapies and restricts their activity to the tumor to minimize peripheral side effects. The broad applicability of these therapies across cancer types means that all patients could benefit from these potentially curative medicines.
Xilio was founded in 2016 and is headquartered in Waltham, Mass. For more information, please visit www.xiliotx.com
Mr. Clancy brings significant strategic, financial and operational leadership experience in the biotechnology and pharmaceutical industry
2020/04/27To Lead XTX201 (Tumor-Selective IL-2) and XTX101 (Tumor-Selective aCTLA-4) into the Clinic while Xilio Continues to Advance its Tumor-Selective Cytokine Pipeline
